Corcept's relacorilant hits phase 3 trial success in ovarian cancer, lifting shares 90%. Click here to find out why I rate ...

Corcept Therapeutics' stock surged over 80% after its Phase 3 ROSELLA trial met its primary goal. See why we still consider ...

Corcept Therapeutics (CORT) stock shot up over 100% yesterday as markets reacted to the company’s announcement of promising outcomes from its ...

Corcept Therapeutics (CORT) closed the last trading session at $91.93, gaining 64.2% over the past four weeks, but there ...

Corcept Therapeutics said on Monday its experimental drug in combination with chemotherapy helped delay progression of a type ...

Corcept Therapeutics’ oral antiglucocorticoid plus chemotherapy slashed risk of ovarian cancer progression by 30% compared to ...

In this article, we are going to take a look at where Corcept Therapeutics Incorporated (NASDAQ:CORT) stands against other ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

The trial outcomes are said to support a new drug application in the US and a European marketing authorisation application.

Josh Lipton takes a closer look at the top stories on Wall Street on today's Market Minute: NewsMax (NMAX) stock skyrockets ...

Learn more about whether Corcept Therapeutics Incorporated or Royalty Pharma plc is a better investment based on AAII's A+ ...

Protagonist (Nasdaq: PTGX) is one of a handful of Bay Area drug developers ready to ask the Food and Drug Administration to ...